A quantitative high-throughput in vitro splicing assay identifies inhibitors of spliceosome catalysis

Molecular and Cellular Biology

Volumn 32, Issue 7, 2012, Pages 1271-1283

  Berg, Michael G ^a   Wan, Lili ^a   Younis, Ihab ^a   Diem, Michael D ^a   Soo, Michael ^a   Wang, Congli ^a   Dreyfuss, Gideon ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 HETEROCYCLIC QUINONE; 1,4 NAPHTHOQUINONE; 2 [(2 HYDROXYETHYL)THIOL] 3 METHYL 1,4 NAPTHOQUINONE; 2 CHLOROMETHYL, 3 METHYL 1,4 NAPTHOQUINONE; 2,3 BIS(METHYLTHIO) 1,4 NAPTHOQUINONE; 3 BENZOYLNAPTHO[1,2 B]FURAN 4,5 DIONE; ANTIBODY; BENZOTHIAZOLE 4,7 DIONE; BIOTIN; BN 82685; CELL EXTRACT; INITIATION FACTOR; INITIATION FACTOR 4AIII; MENADIONE; MESSENGER RNA; N (4 BIPHENYL) 3,4 BIS(2 HYDROXY ETHYLSULPHANYL)MALEIMIDE; NSC 95397; QUINONE DERIVATIVE; RNA; UNCLASSIFIED DRUG; 1,4-NAPHTHOQUINONE; BENZOQUINONE DERIVATIVE; NAPHTHOQUINONE; RNA PRECURSOR; THIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CATALYSIS; CELL COMPONENT; CONTROLLED STUDY; EMBRYO; EXON JUNCTION COMPLEX IMMUNOPRECIPITATION; GENE REARRANGEMENT; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; INTRON; PRIORITY JOURNAL; RNA SPLICING; SPLICEOSOME; TRANSESTERIFICATION; CELL STRAIN HEK293; CHEMISTRY; DRUG EFFECT; HELA CELL; METABOLISM; METHODOLOGY;

EUKARYOTA;

BENZOQUINONES; BIOTIN; HEK293 CELLS; HELA CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNOPRECIPITATION; NAPHTHOQUINONES; RNA PRECURSORS; RNA SPLICING; RNA, MESSENGER; SPLICEOSOMES; THIAZOLES;

EID: 84859984478     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.05788-11     Document Type: Article

References (65)

1. Achsel T, Ahrens K, Brahms H, Teigelkamp S, Luhrmann R. 1998. The human U5-220kD protein (hPrp8) forms a stable RNA-free complex with several U5-specific proteins, including an RNA unwindase, a homologue of ribosomal elongation factor EF-2, and a novel WD-40 protein. Mol. Cell. Biol. 18:6756-6766.
2. Albert BJ, et al. 2009. Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells. Mol. Cancer Ther. 8:2308-2318.
3. Arenas JE, Abelson JN. 1997. Prp43: an RNA helicase-like factor involved in spliceosome disassembly. Proc. Natl. Acad. Sci. U. S. A. 94:11798-11802.
4. Ballut L, et al. 2005. The exon junction core complex is locked onto RNA by inhibition of eIF4AIII ATPase activity. Nat. Struct. Mol. Biol. 12:861-869.
5. Bessonov S, et al. 2010. Characterization of purified human Bact spliceosomal complexes reveals compositional and morphological changes during spliceosome activation and first step catalysis. RNA 16:2384-2403.
6. Bessonov S, Anokhina M, Will CL, Urlaub H, Luhrmann R. 2008. Isolation of an active step I spliceosome and composition of its RNP core. Nature 452:846-850.
7. Blencowe BJ. 2006. Alternative splicing: new insights from global analyses. Cell 126:37-47.
8. Bottner CA, Schmidt H, Vogel S, Michele M, Kaufer NF. 2005. Multiple genetic and biochemical interactions of Brr2, Prp8, Prp31, Prp1 and Prp4 kinase suggest a function in the control of the activation of spliceosomes in Schizosaccharomyces pombe. Curr. Genet. 48:151-161.
9. Brezak MC, et al. 2005. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases. Mol. Cancer Ther. 4:1378-1387.
10. Brisson M, et al. 2004. Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase. Mol. Pharmacol. 66:824-833.
11. Chan CC, et al. 2004. eIF4A3 is a novel component of the exon junction complex. RNA 10:200-209.
12. Chan SP, Kao DI, Tsai WY, Cheng SC. 2003. The Prp19p-associated complex in spliceosome activation. Science 302:279-282.
13. Contour-Galcera MO, Sidhu A, Prevost G, Bigg D, Ducommun B. 2007. What's new on CDC25 phosphatase inhibitors. Pharmacol. Ther. 115:1-12.
14. Cooper TA, Wan L, Dreyfuss G. 2009. RNA and disease. Cell 136:777-793.
15. Dreyfuss G, Kim VN, Kataoka N. 2002. Messenger-RNA-binding proteins and the messages they carry. Nat. Rev. Mol. Cell Biol. 3:195-205.
16. Fukuhara T, et al. 2006. Utilization of host SR protein kinases and RNAsplicing machinery during viral replication. Proc. Natl. Acad. Sci. U. S. A. 103:11329-11333.
17. Galisson F, Legrain P. 1993. The biochemical defects of prp4-1 and prp6-1 yeast splicing mutants reveal that the PRP6 protein is required for the accumulation of the [U4/U6.U5] tri-snRNP. Nucleic Acids Res. 21: 1555-1562.
18. Hagiwara M. 2005. Alternative splicing: a new drug target of the postgenome era. Biochim. Biophys. Acta 1754:324-331.
19. Horowitz DS, Lee EJ, Mabon SA, Misteli T. 2002. A cyclophilin functions in pre-mRNA splicing. EMBO J. 21:470-480.
20. Jurica MS, Moore MJ. 2003. Pre-mRNA splicing: awash in a sea of proteins. Mol. Cell 12:5-14.
21. Kaida D, et al. 2007. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat. Chem. Biol. 3:576-583.
22. Kar S, Wang M, Yao W, Michejda CJ, Carr BI. 2006. PM-20, a novel inhibitor of Cdc25A, induces extracellular signal-regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol. Cancer Ther. 5:1511-1519.
23. Kataoka N, Dreyfuss G. 2008. Preparation of efficient splicing extracts from whole cells, nuclei, and cytoplasmic fractions. Methods Mol. Biol. 488:357-365.
24. Kataoka N, Dreyfuss G. 2004. A simple whole cell lysate system for in vitro splicing reveals a stepwise assembly of the exon-exon junction complex. J. Biol. Chem. 279:7009-7013.
25. Kataoka N, et al. 2000. Pre-mRNA splicing imprints mRNA in the nucleus with a novel RNA-binding protein that persists in the cytoplasm. Mol. Cell 6:673-682.
26. Kim SH, Lin RJ. 1996. Spliceosome activation by PRP2 ATPase prior to the first transesterification reaction of pre-mRNA splicing. Mol. Cell. Biol. 16:6810-6819.
27. Kim VN, et al. 2001. The Y14 protein communicates to the cytoplasm the position of exon-exon junctions. EMBO J. 20:2062-2068.
28. Konarska MM, Sharp PA. 1986. Electrophoretic separation of complexes involved in the splicing of precursors to mRNAs. Cell 46:845-855.
29. Kotake Y, et al. 2007. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat. Chem. Biol. 3:570-575.
30. Krawczak M, Reiss J, Cooper DN. 1992. The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum. Genet. 90:41-54.
31. Kuhn AN, van Santen MA, Schwienhorst A, Urlaub H, Luhrmann R. 2009. Stalling of spliceosome assembly at distinct stages by small-molecule inhibitors of protein acetylation and deacetylation. RNA 15:153-175.
32. Lazo JS, et al. 2001. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J. Med. Chem. 44:4042-4049.
33. Lazo JS, et al. 2002. Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol. Pharmacol. 61:720-728.
34. Le Hir H, Izaurralde E, Maquat LE, Moore MJ. 2000. The spliceosome deposits multiple proteins 20-24 nucleotides upstream of mRNA exonexon junctions. EMBO J. 19:6860-6869.
35. Le Hir H, Nott A, Moore MJ. 2003. How introns influence and enhance eukaryotic gene expression. Trends Biochem. Sci. 28:215-220.
36. Li YM, Casida JE. 1992. Cantharidin-binding protein: identification as protein phosphatase 2A. Proc. Natl. Acad. Sci. U. S. A. 89:11867-11870.
37. Lutzelberger M, et al. 2010. The N terminus of Prp1 (Prp6/U5-102 K) is essential for spliceosome activation in vivo. Nucleic Acids Res. 38:1610-1622.
38. Makarov EM, et al. 2002. Small nuclear ribonucleoprotein remodeling during catalytic activation of the spliceosome. Science 298:2205-2208.
39. Makarova OV, Makarov EM, Liu S, Vornlocher HP, Luhrmann R. 2002. Protein 61K, encoded by a gene (PRPF31) linked to autosomal dominant retinitis pigmentosa, is required for U4/U6*U5 tri-snRNP formation and pre-mRNA splicing. EMBO J. 21:1148-1157.
40. Maquat LE. 2004. Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics. Nat. Rev. Mol. Cell Biol. 5:89-99.
41. Mermoud JE, Cohen P, Lamond AI. 1992. Ser/Thr-specific protein phosphatases are required for both catalytic steps of pre-mRNA splicing. Nucleic Acids Res. 20:5263-5269.
42. Muraki M, et al. 2004. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J. Biol. Chem. 279:24246-24254.
43. Nagradova N. 2007. Enzymes catalyzing protein folding and their cellular functions. Curr. Protein Pept. Sci. 8:273-282.
44. Nakajima H, et al. 1996. New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action. J. Antibiot. (Tokyo) 49:1204-1211.
45. O'Brien K, Matlin AJ, Lowell AM, Moore MJ. 2008. The biflavonoid isoginkgetin is a general inhibitor of Pre-mRNA splicing. J. Biol. Chem. 283:33147-33154.
46. Pilch B, et al. 2001. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. Cancer Res. 61:6876-6884.
47. Schaffert N, Hossbach M, Heintzmann R, Achsel T, Luhrmann R. 2004. RNAi knockdown of hPrp31 leads to an accumulation of U4/U6 disnRNPs in Cajal bodies. EMBO J. 23:3000-3009.
48. Schmittgen TD, Ju JF, Danenberg KD, Danenberg PV. 2003. Inhibition of pre-mRNA splicing by cisplatin and platinum analogs. Int. J. Oncol. 23:785-789.
49. Schneider M, et al. 2010. Human PRP4 kinase is required for stable tri-snRNP association during spliceosomal B complex formation. Nat. Struct. Mol. Biol. 17:216-221.
50. Shi Y, Reddy B, Manley JL. 2006. PP1/PP2A phosphatases are required for the second step of Pre-mRNA splicing and target specific snRNP proteins. Mol. Cell 23:819-829.
51. Shibuya T, Tange TO, Sonenberg N, Moore MJ. 2004. eIF4AIII binds splicedmRNAin the exon junction complex and is essential for nonsensemediated decay. Nat. Struct. Mol. Biol. 11:346-351.
52. Soret J, et al. 2005. Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors. Proc. Natl. Acad. Sci. U. S. A. 102:8764-8769.
53. Staley JP, Guthrie C. 1998. Mechanical devices of the spliceosome: motors, clocks, springs, and things. Cell 92:315-326.
54. Stoilov P, Lin CH, Damoiseaux R, Nikolic J, Black DL. 2008. A highthroughput screening strategy identifies cardiotonic steroids as alternative splicing modulators. Proc. Natl. Acad. Sci. U. S. A. 105:11218-11223.
55. Swanson MS, Dreyfuss G. 1988. RNA binding specificity of hnRNP proteins: a subset bind to the 3′ end of introns. EMBO J. 7:3519-3529.
56. Tamura K, et al. 2000. Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue. Cancer Res. 60:1317-1325.
57. Tazi J, et al. 2005. Selective inhibition of topoisomerase I and various steps of spliceosome assembly by diospyrin derivatives. Mol. Pharmacol. 67:1186-1194.
58. Tazi J, Bakkour N, Stamm S. 2009. Alternative splicing and disease. Biochim. Biophys. Acta 1792:14-26.
59. Tazi J, Durand S, Jeanteur P. 2005. The spliceosome: a novel multifaceted target for therapy. Trends Biochem. Sci. 30:469-478.
60. Wahl MC, Will CL, Luhrmann R. 2009. The spliceosome: design principles of a dynamic RNP machine. Cell 136:701-718.
61. Wan L, et al. 2005. The survival of motor neurons protein determines the capacity for snRNP assembly: biochemical deficiency in spinal muscular atrophy. Mol. Cell. Biol. 25:5543-5551.
62. Wan L, Ottinger E, Cho S, Dreyfuss G. 2008. Inactivation of the SMN complex by oxidative stress. Mol. Cell 31:244-254.
63. Wang ET, et al. 2008. Alternative isoform regulation in human tissue transcriptomes. Nature 456:470-476.
64. Will CL, Luhrmann R. 2010. Spliceosome structure and function. Cold Spring Harb. Perspect. Biol. 3:a003707
65. Younis I, et al. 2010. Rapid-response splicing reporter screens identify differential regulators of constitutive and alternative splicing. Mol. Cell. Biol. 30:1718-1728.